Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

116.84 -0.39 (-0.33%)
Streaming Delayed Price Updated: 3:28 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,704,887
Open 117.27
Bid (Size) 116.83 (3)
Ask (Size) 116.84 (3)
Prev. Close 117.23
Today's Range 116.41 - 117.50
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Advances On Its Cancer Journey
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
+3.18%
+3.18%
1 Month
+1.48%
+1.48%
3 Month
-9.89%
-9.89%
6 Month
-5.48%
-5.48%
1 Year
+8.88%
+8.88%

More News

Read More
Exploring NYSE:MRK's dividend characteristics.
Via Chartmill
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
NYSE:MRK: good value for what you're paying.
Via Chartmill
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
A Closer Look at 8 Analyst Recommendations For Merck & Co
Via Benzinga
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
From Merck & Co., Inc.
Via Business Wire
Is It Too Late to Buy ServiceNow Stock?
Via The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Via Benzinga
Exposures Product Safety
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
Via The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Via MarketBeat
Exposures COVID-19 Product Safety
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Via Benzinga
Merck Scores Two Key Victories With Keytruda In Women's Cancers
Via Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.